Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHA:600557)
China · Delayed Price · Currency is CNY 12.46
-0.28 (-2.20%)
May 20, 2026, 11:29 AM CST
SHA:600557 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,210 | 3,256 | 3,865 | 4,840 | 4,323 | 3,614 |
Other Revenue | 36.53 | 36.53 | 32.75 | 24.28 | 27.46 | 34.95 |
| 3,247 | 3,293 | 3,898 | 4,864 | 4,351 | 3,649 | |
Revenue Growth (YoY) | -4.99% | -15.52% | -19.86% | 11.79% | 19.25% | 20.34% |
Cost of Revenue | 942.53 | 961.05 | 1,065 | 1,254 | 1,214 | 1,024 |
Gross Profit | 2,304 | 2,332 | 2,833 | 3,610 | 3,137 | 2,625 |
Selling, General & Admin | 1,423 | 1,434 | 1,853 | 2,287 | 2,057 | 1,745 |
Research & Development | 604.63 | 607.61 | 638.1 | 846.95 | 605.73 | 499.39 |
Other Operating Expenses | 33.71 | 42.41 | 51.6 | 66.74 | 73.07 | 60.8 |
Operating Expenses | 2,061 | 2,083 | 2,540 | 3,200 | 2,738 | 2,305 |
Operating Income | 242.65 | 249.06 | 293.24 | 409.53 | 399 | 320.11 |
Interest Expense | -14.43 | -14.24 | -22.3 | -22.48 | -1.91 | -11.15 |
Interest & Investment Income | 28.09 | 29.01 | 37.91 | 39.27 | 15.35 | 7.64 |
Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0.15 | 0.06 | 0.15 | - |
Other Non Operating Income (Expenses) | 1.13 | -0.17 | 1.21 | -1.55 | -0.6 | -0.7 |
EBT Excluding Unusual Items | 257.4 | 263.61 | 310.2 | 424.83 | 411.99 | 315.89 |
Gain (Loss) on Sale of Assets | 0.68 | 0.64 | 1.09 | 0.76 | 1.38 | 0.97 |
Asset Writedown | -1.56 | -1.56 | -1.81 | -2.65 | -0.53 | -2.81 |
Other Unusual Items | 93.88 | 93.88 | 75.28 | 25.05 | 32.88 | 14.21 |
Pretax Income | 350.39 | 356.57 | 384.76 | 447.99 | 445.72 | 328.27 |
Income Tax Expense | 48.49 | 49.26 | 3.84 | 3.93 | 3.8 | 3.92 |
Earnings From Continuing Operations | 301.91 | 307.3 | 380.92 | 444.06 | 441.92 | 324.35 |
Minority Interest in Earnings | -2.11 | -3.37 | 10.94 | 20.1 | -7.45 | -3.81 |
Net Income | 299.79 | 303.93 | 391.86 | 464.16 | 434.47 | 320.54 |
Net Income to Common | 299.79 | 303.93 | 391.86 | 464.16 | 434.47 | 320.54 |
Net Income Growth | -11.81% | -22.44% | -15.57% | 6.83% | 35.54% | 21.92% |
Shares Outstanding (Basic) | 565 | 563 | 576 | 573 | 579 | 572 |
Shares Outstanding (Diluted) | 565 | 563 | 576 | 580 | 579 | 572 |
Shares Change (YoY) | -3.38% | -2.33% | -0.68% | 0.16% | 1.20% | -4.21% |
EPS (Basic) | 0.53 | 0.54 | 0.68 | 0.81 | 0.75 | 0.56 |
EPS (Diluted) | 0.53 | 0.54 | 0.68 | 0.80 | 0.75 | 0.56 |
EPS Growth | -8.72% | -20.59% | -15.00% | 6.67% | 33.93% | 27.27% |
Free Cash Flow | -13.32 | 88.81 | 225.8 | 661.03 | 784.85 | 736.77 |
Free Cash Flow Per Share | -0.02 | 0.16 | 0.39 | 1.14 | 1.35 | 1.29 |
Dividend Per Share | - | - | - | 0.372 | 0.220 | - |
Dividend Growth | - | - | - | 69.11% | - | - |
Gross Margin | 70.97% | 70.81% | 72.69% | 74.22% | 72.11% | 71.95% |
Operating Margin | 7.47% | 7.56% | 7.52% | 8.42% | 9.17% | 8.77% |
Profit Margin | 9.23% | 9.23% | 10.05% | 9.54% | 9.99% | 8.79% |
Free Cash Flow Margin | -0.41% | 2.70% | 5.79% | 13.59% | 18.04% | 20.19% |
EBITDA | 424.31 | 434.32 | 492.88 | 604.4 | 588.83 | 507.11 |
EBITDA Margin | 13.07% | 13.19% | 12.65% | 12.43% | 13.53% | 13.90% |
D&A For EBITDA | 181.66 | 185.26 | 199.64 | 194.88 | 189.83 | 187 |
EBIT | 242.65 | 249.06 | 293.24 | 409.53 | 399 | 320.11 |
EBIT Margin | 7.47% | 7.56% | 7.52% | 8.42% | 9.17% | 8.77% |
Effective Tax Rate | 13.84% | 13.82% | 1.00% | 0.88% | 0.85% | 1.19% |
Revenue as Reported | 3,247 | 3,293 | 3,898 | 4,864 | 4,351 | 3,649 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.